RALEIGH, N.C.--(

--(

BUSINESS WIRE

商业热线

)--

)--

Caidya

Cady ady

, a leading global, mid-sized CRO, today announced the appointment of

，一家领先的全球中型首席风险官，今天宣布任命

Brandon Pallott

布兰登 帕洛特

as its new chief commercial officer (CCO). In this role, he will focus on implementing transformative commercial strategies to ensure the organization not only adapts to the evolving market landscape but also leads the industry forward. On the heels of Caidya’s recent

担任新任首席商务官（CCO）。在这个职位上，他将专注于实施变革性商业战略，以确保组织不仅适应不断变化的市场格局，而且引领行业前进。在Caidya最近

investment of $165M

投资1.65亿美元

from Rubicon Founders, the company is poised to continue and improve its ability to deliver exceptional outcomes for the sponsors and patients.

从Rubicon创始人那里，该公司准备继续并提高其为赞助商和患者提供卓越成果的能力。

A collaborative and results-driven visionary executive, Brandon has successfully led high-performing, cross-functional teams in commercial, business development, and revenue-generating roles for more than 20 years. With deep expertise in crafting and executing go-to-market strategies across clinical and commercial arenas in the life sciences industry, he has consistently demonstrated his ability to build strategic partnerships, drive innovative initiatives, and expand markets to achieve commercial excellence..

Brandon是一位具有合作精神和成果导向的富有远见的高管，20多年来，他成功领导了商业、业务开发和创收领域的高绩效、跨职能团队。凭借在生命科学行业临床和商业领域制定和执行走向市场战略的深厚专业知识，他始终展示了建立战略合作伙伴关系、推动创新举措和扩大市场以实现商业卓越的能力。。

Caidya’s Chief Executive Officer,

Caidya的首席执行官，

Barbara Lopez Kunz

芭芭拉·洛佩兹·昆茨

, said, “I’m thrilled to have Brandon join our leadership team, and I’m confident in his ability to guide us in elevating our clients’ experience — from the very first contact to every touchpoint thereafter.”

他说：“我很高兴布兰登加入我们的领导团队，我相信他有能力指导我们提升客户的体验-从第一次接触到之后的每个接触点。”

“I am beyond excited to join Caidya at the cusp of this next phase of our growth,” said Pallott. “And I’m eager to start working with our talented commercial and operational teams as we collaborate with biopharma partners to help them bring treatments to patients.”

。“我渴望与我们有才能的商业和运营团队合作，与生物制药合作伙伴合作，帮助他们为患者带来治疗。”

For more information about Caidya and its services, please visit

有关Caidya及其服务的更多信息，请访问

www.caidya.com

www.caidya.com

.

.

About Caidya

关于Caidya

Caidya

Cady ady

is a global, mid-sized clinical research organization (CRO) dedicated to advancing healthcare innovation and partnering with biopharma sponsors to bring innovative therapies for unmet medical conditions to our global community. With full-service capabilities and a strategic footprint in 23 countries and regions, our global network provides broad access to diverse patient populations across the Americas, Europe, and APAC.

是一家全球中型临床研究组织（CRO），致力于推进医疗保健创新，并与生物制药赞助商合作，为我们的全球社区带来针对未满足医疗条件的创新疗法。凭借全方位服务能力和在23个国家和地区的战略足迹，我们的全球网络为美洲、欧洲和亚太地区的不同患者群体提供了广泛的服务。

Caidya’s in-depth therapeutic and operational expertise spans oncology and hematology, rare and pediatric diseases as well as other fast-growing therapeutic areas where we help our biopharma partners conduct studies with greater efficiency and confidence..

Caidya深入的治疗和操作专业知识涵盖肿瘤学和血液学，罕见病和儿科疾病以及其他快速发展的治疗领域，我们帮助我们的生物制药合作伙伴以更高的效率和信心进行研究。。

Caidya delivers comprehensive clinical trial services from regulatory strategy and submissions, medical affairs, clinical operations, data management, biometrics, pharmacovigilance, and quality management, through post-approval surveillance. Our data-driven, evidence-based decision making ensures the highest quality standards across all stages of the drug development process..

Caidya通过批准后监督提供全面的临床试验服务，包括监管策略和提交、医疗事务、临床操作、数据管理、生物特征识别、药物警戒和质量管理。我们的数据驱动，循证决策确保了药物开发过程各个阶段的最高质量标准。。